Variant position: 21 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Protein sequence length: 173 The length of the canonical sequence.
Location on the sequence:
The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.
Residue conservation: The multiple alignment of the region surrounding the variant against various orthologous sequences.
Human MDVTIQHPWFKRTLGPFYPS RLFDQFFGEGLFEYDLLPFLS
Rhesus macaque MDVTIQHPWFKRTLGPFYPS RLFDQFFGEGLFEYDLLPFLS
Mouse MDVTIQHPWFKRALGPFYPS RLFDQFFGEGLFEYDLLPFLS
Rat MDVTIQHPWFKRALGPFYPS RLFDQFFGEGLFEYDLLPFLS
Pig MDIAIQHPWFKRALGPFYPS RLFDQFFGEGLFEYDLLPFLS
Bovine MDIAIQHPWFKRTLGPFYPS RLFDQFFGEGLFEYDLLPFLS
Rabbit MDVTIQHPWFKRTLGPFYPS RLFDQFFGEGLFEYDLLPFLS
Sheep MDIAIQHPWFKRTLGPFYPS RLFDQFFGEGLFEYDLLPFLS
Cat MDIAIQHPWFKRALGPFYPS RLFDQFFGEGLFEYDLLPFLS
Horse MDIAIQHPWFKRALGPFYPS RLFDQFFGEGLFEYDLLPFLS
Chicken MDITIQHPWFKRALGPLIPS RLFDQFFGEGLLEYDLLPLFS
Sequence annotation in neighborhood: The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:
Type: the type of sequence feature. Positions: endpoints of the sequence feature. Description: contains additional information about the feature.
Type Positions Description
1 – 173 Alpha-crystallin A chain
1 – 172 Alpha-crystallin A(1-172)
1 – 168 Alpha-crystallin A(1-168)
1 – 162 Alpha-crystallin A(1-162)
1 – 63 Required for complex formation with BFSP1 and BFSP2
1 – 1 Susceptible to oxidation
18 – 18 Susceptible to oxidation
34 – 34 Susceptible to oxidation
1 – 1 N-acetylmethionine
6 – 6 Deamidated glutamine; partial
Congenital cataract and macular hypoplasia in humans associated with a de novo mutation in CRYAA and compound heterozygous mutations in P.
Graw J.; Klopp N.; Illig T.; Preising M.N.; Lorenz B.;
Graefes Arch. Clin. Exp. Ophthalmol. 244:912-919(2006)
Cited for: VARIANT CTRCT9 LEU-21;
Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. They are not in any way intended to be used as a substitute for professional medical advice, diagnostic, treatment or care.